Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Flex Announces Change in the Financing Condition Under Its Tender Offer for Any and All 4.625% Notes Due 2020

Published

on

Reading Time: 4 minutes

SAN JOSE, Calif.–(BUSINESS WIRE)–Flex (Nasdaq: FLEX) today announced that it has amended the financing
condition for its previously-announced cash tender offer (the “Tender
Offer”) for any and all of its outstanding 4.625% Notes due 2020 (the
“2020 Notes”). In addition to the other terms and conditions of the
Tender Offer, the Tender Offer is now subject to the successful
completion by Flex of its previously-announced offering (the “Offering”)
of $450 million aggregate principal amount of 4.875% notes due 2029 (the
“New Notes”). The Company intends to use the net proceeds from the
Offering, together with available cash, to effect the repurchase of the
2020 Notes validly tendered and accepted for purchase pursuant to the
Tender Offer and the redemption, in accordance with the terms of the
indenture governing the 2020 Notes, of any and all 2020 Notes remaining
outstanding after the Tender Offer, including the payment of any
premiums, accrued interest and costs and expenses incurred in connection
with the foregoing. If any 2020 Notes remain outstanding after the
consummation of the Tender Offer, Flex expects (but is not obligated) to
redeem such 2020 Notes in accordance with the terms and conditions set
forth in the related indenture. The Offering is not conditioned on the
completion of the Tender Offer.

The Tender Offer is being made on the terms and subject to the
conditions set forth in the Offer to Purchase dated May 30, 2019 (the
“Offer to Purchase”) and the related letter of transmittal and notice of
guaranteed delivery (collectively, the “Offer Documents”), subject to
the above-described amendment to the financing condition.

The Tender Offer will expire at 5:00 p.m., New York City time, on June
5, 2019, unless extended or earlier terminated as described in the Offer
to Purchase.

The Company has engaged J.P. Morgan Securities LLC, Citigroup Global
Markets Inc. and BNP Paribas Securities Corp. to act as dealer managers
(collectively, the “Dealer Managers”) in connection with the Tender
Offer, and has appointed D.F. King & Co., Inc. (“DF King”) to serve as
the tender agent and information agent for the Tender Offer. Copies of
the Offer Documents are available via the Tender Offer website at http://www.dfking.com/flex
or by contacting DF King in New York via email at [email protected]
or via telephone at (212) 269-5550 (banks and brokers) or (800) 967-4607
(all others). Questions regarding the terms of the Tender Offer should
be directed to J.P. Morgan Securities LLC at (212) 834-8553 (collect) or
(866) 834-4666 (toll-free), Citigroup Global Markets Inc. at (212)
723-6106 (collect) or (800) 558-3745 (toll-free) or BNP Paribas
Securities Corp. at (212) 841-3059 (collect) or (888) 210-4358
(toll-free).

None of Flex, its board of directors, the Dealer Managers, DF King or
the trustee for the 2020 Notes, or any of their respective affiliates,
is making any recommendation as to whether Holders should tender any
2020 Notes in response to the Tender Offer. Holders must make their own
decision as to whether to tender any of their 2020 Notes and, if so, the
principal amount of 2020 Notes to tender.

This press release is neither an offer to purchase nor a solicitation of
an offer to sell any of the 2020 Notes, or an offer to sell or a
solicitation of an offer to purchase the New Notes pursuant to the
Offering nor is it a solicitation for acceptance of the Tender Offer,
nor shall it constitute a notice of redemption under the indenture
governing the 2020 Notes. Flex is making the Tender Offer only by, and
pursuant to the terms of, the Offer Documents. The Tender Offer is not
being made in any jurisdiction in which the making or acceptance thereof
would not be in compliance with the securities, blue sky or other laws
of such jurisdiction.

About Flex

Flex Ltd. (Reg. No. 199002645H) is the Sketch-to-Scale®
solutions provider that designs and builds intelligent products
globally. With approximately 200,000 employees across 30 countries, Flex
provides innovative design, engineering, manufacturing, real-time supply
chain insight and logistics services to companies of all sizes across
industries and markets.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of U.S. securities laws, including statements related to the
Offering, the Tender Offer and any potential redemption of 2020 Notes
not tendered in the Tender Offer. These forward-looking statements
involve risks and uncertainties that could cause the actual results to
differ materially from those anticipated by these forward-looking
statements, including the risk that the Tender Offer, the Offering or
the redemption of the 2020 Notes may not be completed on the proposed
terms, or at all. Readers are cautioned not to place undue reliance on
these forward-looking statements. The following risks, among others,
could affect our business and financial performance: future revenues and
earnings may not be achieved as expected; the challenges of effectively
managing our operations, including our ability to control costs and
manage changes in our operations; litigation and regulatory
investigations and proceedings; compliance with legal and regulatory
requirements; the possibility that benefits of our restructuring actions
may not materialize as expected; the expected revenue and margins from
recently launched programs may not be realized; our dependence on a
small number of customers; the impact of component shortages, including
their impact on our revenues; geopolitical risk, including the
termination and renegotiation of international trade agreements and
trade policies, including the impact of tariffs and related regulatory
actions; recently proposed changes or future changes in tax laws in
certain jurisdictions where we operate could materially impact our tax
expense; the effects that the current macroeconomic environment could
have on our business and demand for our products; and the effects that
current credit and market conditions could have on the liquidity and
financial condition of our customers and suppliers, including any impact
on their ability to meet their contractual obligations.

Additional information concerning these and other risks is described
under “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in our reports on Forms
10-K and 10-Q that we file with the U.S. Securities and Exchange
Commission. The forward-looking statements in this press release are
based on current expectations and Flex assumes no obligation to update
these forward-looking statements, except as required by law.

Contacts

Kevin Kessel, CFA
Vice President, Investor Relations
(408)
576-7985
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

SCHWAZZE

Schwazze Announces Fourth Quarter and Full Year 2023 Financial Results

Published

on

schwazze-announces-fourth-quarter-and-full-year-2023-financial-results

 FY 2023 Revenue of $172.4 Million; Income from Operations of $3.3 Million; Adjusted EBITDA of $53.4 Million or 31% of Revenue

 Generated $12.2 Million of Operating Cash Flow in FY 2023

DENVER, March 27, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the fourth quarter and full year ended December 31, 2023.

“This past year, the Schwazze team delivered solid top-line growth in two highly competitive markets with 31% adjusted EBITDA margins and improved operating cash flow,” said Forrest Hoffmaster, Interim CEO of Schwazze. “We continued to sharpen our retail strategy while expanding our store footprint by more than 50% to 63 dispensaries across our two markets. Although the Colorado and New Mexico markets were pressured in 2023, we have built a solid foundation with best-in-class service for our patients and customers. Internally, we are also relentlessly focused on maximizing the operating efficiencies of our manufacturing and cultivation facilities to drive higher yields, improved flower quality, and greater output.”

“With strong demand and over 680 recreational retail stores at year-end, the competitive landscape in Colorado is fierce, underscoring the importance of our investments in and attention to elevating the customer experience. We significantly outpaced the market in Q4 on a sequential and year-over-year basis and expect to bolster our growth through improvements in customer acquisition, retention, and loyalty, as well as in the overall retail experience. Additionally, we are beginning to see wholesale pricing stabilize, which we anticipate will continue based on plant counts and ongoing retail pricing pressure.”

“In New Mexico, the proliferation of new licenses has led to increased competition and aggressive pricing strategies from certain players. Cannabis sales in the state were up 18% across a store base that was over 50% higher year-over-year in Q4, leading to lower average revenue per store. While we are beginning to see a slow-down in net new store openings, we anticipate a challenging market ahead. We remain focused on cost optimization and asset utilization while implementing a balanced pricing and promotional strategy to drive traffic into our stores, where we believe we excel in delivering an elevated retail experience. We are committed to fulfilling our promise of being the retailer of choice in New Mexico.”

“Looking ahead, we are optimistic about the regulatory momentum in the industry at large. In the meantime, we will continue to elevate the customer experience, improve our loyalty program, increase our cost efficiencies, and enhance our retail assets. Our team has a demonstrated track record of executing in competitive markets like Colorado and New Mexico where we remain one of the largest operators. We look forward to driving growth and profitability across each of our markets in 2024.”

Fourth Quarter 2023 Financial Summary

$ in Thousands USD

Q4 2023

Q3 2023

Q4 2022

Total Revenue

$43,325

$46,747

$40,147

Gross Profit

$7,034

$21,438

$21,719

Adjusted Gross Profit[1]

$20,180

$21,438

$21,719

Operating Expenses

$23,276

$12,514

$24,224

Income (Loss) from Operations

$(16,242)

$8,924

$(2,505)

Adjusted EBITDA[2]

$10,953

$14,119

$13,285

Operating Cash Flow

$3,452

$6,946

$6,260

Full Year 2023 Financial Summary

$ in Thousands USD

FY 2023

FY 2022

Total Revenue

$172,448

$159,379

Gross Profit

$76,024

$80,289

Adjusted Gross Profit1

$89,170

$86,830

Operating Expenses

$72,735

$67,434

Income from Operations

$3,289

$12,855

Adjusted EBITDA2

$53,412

$52,010

Operating Cash Flow

$12,201

$6,694

___________________________

1  Adjusted Gross Profit is a non-GAAP measure as defined by the SEC and represents gross profit excluding non-cash inventory adjustments. The Company uses Adjusted Gross Profit as it believes it better explains the results of its core business. See “ADJUSTED GROSS PROFIT RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Full Year 2023 Operational Highlights

  • Expanded the Company’s retail footprint by more than 50% in New Mexico and Colorado to 63 dispensaries.
  • Completed the acquisition of Everest Apothecary, adding 14 dispensaries, one cultivation facility, and one manufacturing plant to the Company’s New Mexico operations.
  • Acquired Standing Akimbo, the largest medical cannabis dispensary in Colorado, and opened the Company’s first medical dispensary in Colorado Springs under the Standing Akimbo banner.
  • Acquired two Colorado retail dispensaries in Fort Collins and Garden City from Smokey’s.
  • Unveiled an enhanced, custom ecommerce platform in New Mexico under the R. Greenleaf banner.
  • Increased wholesale penetration in Colorado and New Mexico by over 3x year-over-year to more than 27% total door penetration in both states.
  • Grew Lowell Farms pre-roll sales by over 250% in Colorado where it is now the #1 pre-roll in the state. In addition, Lowell is in six of the largest Colorado accounts and will be available for wholesale in New Mexico starting April 1st, 2024.
  • Grew sales with Wana, our fan-favorite gummies brand, by 48% in New Mexico where it is now in 130 doors with eight of the top ten accounts in the state.

Fourth Quarter 2023 Financial Results

Total revenue in the fourth quarter of 2023 increased 8% to $43.3 million compared to $40.1 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period and increased wholesale revenue, partially offset by pricing pressure from the proliferation of new licenses in New Mexico.

Gross profit for the fourth quarter of 2023 was $7.0 million or 16.2% of total revenue, compared to $21.7 million or 54.1% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. Adjusted gross profit, which excludes non-cash inventory adjustments, for the fourth quarter of 2023 was $20.2 million or 46.6% of revenue.

Operating expenses for the fourth quarter of 2023 were $23.3 million compared to $24.2 million for the same quarter last year. The decrease was primarily due to a lower impairment charge in the fourth quarter of 2023. This was partially offset by an increase in four-wall SG&A expenses associated with the 22 additional stores in Colorado and New Mexico that are still ramping, as well as greater salaries and stock-based compensation.

Loss from operations for the fourth quarter of 2023 was $16.2 million compared to $2.5 million in the same quarter last year. The decrease was driven by the aforementioned lower gross profit, primarily related to the non-cash inventory adjustment. Net loss was $33.9 million for the fourth quarter of 2023 compared to $27.3 million for the same quarter last year.

Adjusted EBITDA for the fourth quarter of 2023 was $11.0 million or 25.3% of revenue, compared to $13.3 million or 33.1% of revenue for the same quarter last year. The decrease in Adjusted EBITDA margin was primarily driven by higher operating expenses associated with the 22 additional stores that are still ramping.

As of December 31, 2023, cash and cash equivalents were $19.2 million compared to $38.9 million on December 31, 2022. Total debt as of December 31, 2023, was $156.8 million compared to $127.8 million on December 31, 2022.

Conference Call

The Company will conduct a conference call today, March 27, 2024, at 5:00 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2023.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, March 27, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 38840334
Webcast: SHWZ Q4 & FY 2023 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 840334

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars

For the Three Months Ended

For the Twelve Months Ended

December 31,

December 31,

2023

2022

2023

2022

(Unaudited)

(Unaudited)

(Audited)

(Audited)

Operating Revenues

Retail

$

39,592,779

$

36,868,429

$

155,463,816

$

141,254,893

Wholesale

3,730,749

3,158,670

16,765,425

17,819,938

Other

1,287

120,188

218,545

304,388

Total Revenue

43,324,815

40,147,287

172,447,786

159,379,219

Total Cost of Goods & Services

36,291,059

18,428,528

96,424,150

79,090,461

Gross Profit

7,033,756

21,718,759

76,023,636

80,288,758

Operating Expenses

Selling, General and Administrative Expenses

10,848,029

8,922,627

39,916,518

29,036,962

Professional Services

1,115,457

1,112,975

3,558,501

6,722,554

Loss on Impairment

1,810,890

8,011,405

1,801,740

8,011,405

Salaries

6,561,800

5,292,996

23,883,354

20,990,290

Stock Based Compensation

2,952,669

883,890

3,574,831

2,672,713

Total Operating Expenses

23,288,845

24,223,893

72,734,944

67,433,924

Income from Operations

(16,255,089)

(2,505,134)

3,288,692

12,854,834

Other Income (Expense)

Interest Expense, net

(8,112,391)

(6,827,557)

(32,069,082)

(30,139,645)

Unrealized Gain (Loss) on Derivative Liabilities

1,384,228

(9,690,200)

15,870,233

18,414,760

Other Loss

68,400

3,736

68,400

24,136

Loss on Business Disposition

(1,968,807)

(4,684,366)

(1,968,807)

(4,684,366)

Unrealized Gain (Loss) on Investments

3,083

1,816

(39,270)

Total Other Income (Expense)

(8,628,570)

(21,195,304)

(18,097,441)

(16,424,385)

Pre-Tax Net Income (Loss)

(24,883,659)

(23,700,438)

(14,808,749)

(3,569,551)

Provision for Income Taxes

4,494,049

3,638,695

19,740,595

14,898,064

Net Income (Loss)

$

(29,377,708)

$

(27,339,133)

$

(34,549,344)

$

(18,467,615)

Less: Accumulated Preferred Stock Dividends for the Period

(1,541,341)

(2,508,677)

(8,154,993)

(7,802,809)

Net Income (Loss) Attributable to Common Stockholders

$

(30,919,049)

$

(29,847,810)

$

(42,704,337)

$

(26,270,424)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.43)

$

(0.57)

$

(0.66)

$

(0.49)

Diluted Earnings (Loss) per Share

$

(0.43)

$

(0.57)

$

(0.66)

$

(0.49)

Weighted Average Number of Shares Outstanding – Basic

71,680,200

53,637,003

64,535,245

53,637,003

Weighted Average Number of Shares Outstanding – Diluted

71,680,200

53,637,003

64,535,245

53,637,003

Comprehensive Income (Loss)

$

(29,377,708)

$

(27,339,133)

$

(34,549,344)

$

(18,467,615)

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars

For the Twelve Months Ended

December 31,

2023

2022

(Audited)

(Audited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(34,549,344)

$

(18,467,615)

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

20,933,541

10,660,172

Non-Cash Interest Expense

4,024,604

4,118,391

Impairment of Goodwill

1,801,740

8,011,405

Non-Cash Lease Expense

7,648,531

3,910,679

Deferred Taxes

(2,090,967)

502,070

Loss on Disposition of Business Units

1,968,807

4,684,369

Change in Derivative Liabilities

(15,870,233)

(18,414,760)

Amortization of Debt Issuance Costs

1,686,049

1,686,048

Amortization of Debt Discount

8,523,493

7,484,613

(Gain) Loss on Investments, net

(1,816)

39,270

Stock Based Compensation

3,590,473

812,073

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

927,259

(105,185)

Inventory

4,571,069

789,399

Prepaid Expenses & Other Current Assets

1,579,349

(2,770,179)

Other Assets

263,419

(248,682)

Change in Operating Lease Liabilities

(7,498,128)

(13,113,041)

Accounts Payable & Other Liabilities

(3,241,850)

11,845,245

Income Taxes Payable

17,934,967

5,270,074

Net Cash Provided by (Used in) Operating Activities

12,200,963

6,694,346

Cash Flows from Investing Activities:

Collection of Notes Receivable

11,944

Cash Consideration for Acquisition of Business, net of Cash Acquired

(15,834,378)

(58,981,226)

Purchase of Fixed Assets

(7,865,654)

(14,007,892)

Purchase of Intangible Assets

(2,750,000)

Investment in Private Entity

(2,000,000)

Net Cash Provided by (Used in) Investing Activities

(26,438,088)

(74,989,118)

Cash Flows from Financing Activities:

Payment on Notes Payable

(5,354,218)

(134,498)

Proceeds from Issuance of Common Stock

978,308

Payment for Statutory Withholdings on RSU

(108,978)

Net Cash Provided by (Used in) Financing Activities

(5,463,196)

843,810

Net (Decrease) in Cash & Cash Equivalents

(19,700,321)

(67,450,962)

Cash & Cash Equivalents at Beginning of Period

38,949,253

106,400,216

Cash & Cash Equivalents at End of Period

$

19,248,932

$

38,949,253

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

17,896,954

$

15,243,990

Cash Paid for Income Taxes

5,000,000

12,340,000

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars

For the Three Months Ended

For the Twelve Months Ended

December 31,

December 31,

2023

2022

2023

2022

Net Income (Loss)

$

(29,364,680)

$

(27,339,133)

$

(34,549,344)

$

(18,467,615)

Interest Expense, net

8,112,391

6,827,557

32,069,082

30,139,645

Provision for Income Taxes

4,494,049

3,638,695

19,740,595

14,898,064

Other (Income) Expense, net of Interest Expense

516,180

14,367,747

(13,971,641)

(13,715,260)

Depreciation & Amortization

3,162,425

3,701,128

18,970,960

12,524,677

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

(13,079,635)

$

1,195,994

$

22,259,652

$

25,379,511

Non-Cash Stock Compensation

1,597,157

883,890

2,219,319

2,672,713

Deal Related Expenses

2,196,733

1,914,820

5,528,048

6,822,111

Capital Raise Related Expenses

1,779

(257,271)

38,559

533,958

Inventory Adjustment to Fair Market Value for

Purchase Accounting

5,792,488

5,792,488

6,541,651

One-Time Inventory Impairment

7,353,972

7,353,972

One-Time Goodwill Impairment

1,801,740

8,011,405

1,801,740

8,011,405

Severance

111,752

263,374

537,584

334,910

Retention Program Expenses

505,655

Employee Relocation Expenses

5,065

(3,750)

70,107

15,360

Pre-Operating & Dark Carry Expenses

2,663,824

1,027,738

2,663,824

1,027,738

One-Time Legal Settlements

1,204,058

440,000

1,204,058

440,000

Other Non-Recurring Items

1,304,501

(191,674)

3,436,773

230,858

Adjusted EBITDA (non-GAAP)

$

10,953,434

$

13,284,526

$

53,411,779

$

52,010,215

Revenue

43,324,815

40,147,287

172,447,786

159,379,219

Adjusted EBITDA Percent

25.3 %

33.1 %

31.0 %

32.6 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-fourth-quarter-and-full-year-2023-financial-results-302101678.html

Continue Reading

Cannabis

Hemp, Inc. Announces Significant Progress in Hemp Seed Meal Approval for Laying Hen Diets

Published

on

Continue Reading

Cannabis

Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors

Published

on

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania